Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

specialty care

- PMLiVE

AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

- PMLiVE

Kite and Epic Bio announce cancer cell therapy collaboration agreement

The partnership centres around Epic Bio’s proprietary gene regulation platform

- PMLiVE

Merck KGaA and Hengrui Pharmaceuticals announce oncology partnership worth over €1.4bn

The deal includes a next-generation PARP1 inhibitor and an antibody drug conjugate

- PMLiVE

GSK’s Jemperli combination shows promise in phase 3 endometrial cancer trial

Up to 20% of endometrial cancer patients will have advanced disease at the time of diagnosis

- PMLiVE

Roche collaborates with Ibex and Amazon Web to improve cancer diagnosis

Integrated artificial intelligence-based tools will support clinicians’ decisions in cancer diagnosis

- PMLiVE

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

Approximately 16,000 people in the US are diagnosed with myelodysplastic syndromes every year

- PMLiVE

UCL study finds use of existing drugs improves cervical cancer outcomes

The approach was shown to reduce the risk of death or cancer recurrence by 35%

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced lung cancer

Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases

- PMLiVE

Pfizer’s proposed $43bn Seagen acquisition unconditionally approved by EC

The transaction is not expected to raise competition concerns or impact treatment prices

- PMLiVE

Merck and Daiichi Sankyo announce ADC agreement worth up to $22bn

The companies will jointly develop and commercialise three of Daiichi Sankyo’s cancer candidates

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer trial

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

Medscape Medical Affairs Selected as Finalist for 2023 Pharmaceutical Market Excellence Awards (PMEAs)

We’re delighted to announce that two Global Medscape Medical Affairs programmes have been shortlisted in various categories for The Pharmaceutical Market Excellence Awards (PMEAs). The two programmes selected both succeeded...

Medscape Medical Affairs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links